Stereospecific interactions are necessary for Alzheimer disease amyloid-β toxicity

Neurobiology of Aging

Volumn 32, Issue 2, 2011, Pages 235-248

  Ciccotosto, Giuseppe D ^a,b,c   Tew, Deborah J ^a,b,c   Drew, Simon C ^a,b,c,d   Smith, Danielle G ^a,b,c   Johanssen, Timothy ^a,b,c   Lal, Varsha ^c   Lau, Tong Lay ^a,b   Perez, Keyla ^b,c   Curtain, Cyril C ^d   Wade, John D ^a   Separovic, Frances ^a,b   Masters, Colin L ^c   Smith, Jeffrey P ^a,c   Barnham, Kevin J ^a,b,c   Cappai, Roberto ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Annexin V; Chiral; Cortex; Long term potentiation; Membrane phospholipid; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; COPPER; LIPOCORTIN 5; PEPTIDE DERIVATIVE; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOPHYSICS; BRAIN CORTEX; CELL ADHESION; CONTROLLED STUDY; ENANTIOMER; LONG TERM POTENTIATION; MEMBRANE BINDING; METAL BINDING; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN LIPID INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; WILD TYPE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANNEXIN A5; BIOPHYSICS; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ELECTRON SPIN RESONANCE SPECTROSCOPY; EMBRYO, MAMMALIAN; HYDROGEN PEROXIDE; LONG-TERM POTENTIATION; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NEURONS; PATCH-CLAMP TECHNIQUES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; THIAZOLES; TIME FACTORS; TYROSINE;

EID: 78649901710     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.02.018     Document Type: Article

References (52)

1. Andree H.A., Stuart M.C., Hermens W.T., Reutelingsperger C.P., Hemker H.C., Frederik P.M., Willems G.M. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J. Biol. Chem. 1992, 267:17907-17912.
2. Andreu J.M., Timasheff S.N. The measurement of cooperative protein self-assembly by turbidity and other techniques. Methods Enzymol. 1986, 130:47-59.
3. Arispe N. Architecture of the Alzheimer's AβP ion channel pore. J. Membr. Biol. 2004, 197:33-48.
4. Atwood C.S., Perry G., Zeng H., Kato Y., Jones W.D., Ling K.Q., Huang X., Moir R.D., Wang D., Sayre L.M., Smith M.A., Chen S.G., Bush A.I. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-β. Biochemistry 2004, 43:560-568.
5. Barnham K.J., Ciccotosto G.D., Tickler A.K., Ali F.E., Smith D.G., Williamson N.A., Lam Y.H., Carrington D., Tew D., Kocak G., Volitakis I., Separovic F., Barrow C.J., Wade J.D., Masters C.L., Cherny R.A., Curtain C.C., Bush A.I., Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 2003, 278:42959-42965.
6. Barnham K.J., Haeffner F., Ciccotosto G.D., Curtain C.C., Tew D., Mavros C., Beyreuther K., Carrington D., Masters C.L., Cherny R.A., Cappai R., Bush A.I. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 2004, 18:1427-1429.
7. Barnham K.J., Kenche V.B., Ciccotosto G.D., Smith D.P., Tew D.J., Liu X., Perez K., Cranston G.A., Johanssen T.J., Volitakis I., Bush A.I., Masters C.L., White A.R., Smith J.P., Cherny R.A., Cappai R. Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6813-6818.
8. Bateman D.A., McLaurin J., Chakrabartty A. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. BMC Neurosci. 2007, 8:29.
9. Bitan G., Lomakin A., Teplow D.B. Amyloid β-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 2001, 276:35176-35184.
10. Boon J.M., Lambert T.N., Sisson A.L., Davis A.P., Smith B.D. Facilitated phosphatidylserine (PS) flip-flop and thrombin activation using a synthetic PS scramblase. J. Am. Chem. Soc. 2003, 125:8195-8201.
11. Bretscher M.S. Asymmetrical lipid bilayer structure for biological membranes. Nat. New Biol. 1972, 236:11-12.
12. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003, 26:207-214.
13. Cappai R., Barnham K.J. Delineating the Mechanism of Alzheimer's disease Aβ peptide neurotoxicity. Neurochem. Res. 2007, 33:526-532.
14. Cappai R., Barnham K.J. Molecular determinants of Alzheimer's disease Aβ peptide neurotoxicity. Future Neurol. 2007, 4:397-409.
15. Castegna A., Lauderback C.M., Mohmmad-Abdul H., Butterfield D.A. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res. 2004, 1004:193-197.
16. Ciccotosto G.D., Tew D., Curtain C.C., Smith D., Carrington D., Masters C.L., Bush A.I., Cherny R.A., Cappai R., Barnham K.J. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J. Biol. Chem. 2004, 279:42528-42534.
17. Cribbs D.H., Pike C.J., Weinstein S.L., Velazquez P., Cotman C.W. All-D-enantiomers of beta-amyloid exhibit similar biological properties to all-L-beta-amyloids. J. Biol. Chem. 1997, 272:7431-7436.
18. Daleke D.L. Regulation of transbilayer plasma membrane phospholipid asymmetry. J. Lipid Res. 2003, 44:233-242.
19. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005, 280:17294-17300.
20. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10417-10422.
21. Harper J.D., Lansbury P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997, 66:385-407.
22. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., Scarpa R.C., Saunders A.J., Lim J., Moir R.D., Glabe C., Bowden E.F., Masters C.L., Fairlie D.P., Tanzi R.E., Bush A.I. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 1999, 274:37111-37116.
23. Hung L.W., Ciccotosto G.D., Giannakis E., Tew D.J., Perez K., Masters C.L., Cappai R., Wade J.D., Barnham K.J. Amyloid-beta peptide (Aβ) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J. Neurosci. 2008, 28:11950-11958.
24. Kang J., Lemaire H., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K., Multhaup G., Beyreuther K., Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
25. Karr J.W., Szalai V.A. Role of aspartate-1 in Cu(II) binding to the amyloid-beta peptide of Alzheimer's disease. J. Am. Chem. Soc. 2007, 129:3796-3797.
26. Kourie J.I. Mechanisms of amyloid beta protein-induced modification in ion transport systems: implications for neurodegenerative diseases. Cell. Mol. Neurobiol. 2001, 21:173-213.
27. Kowalik-Jankowska T., Ruta M., Wisniewska K., Lankiewicz L. Coordination abilities of the 1-16 and 1-28 fragments of beta-amyloid peptide towards copper(II) ions: a combined potentiometric and spectroscopic study. J. Inorg. Biochem. 2003, 95:270-282.
28. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6448-6453.
29. Lampl Y., Lorberboym M., Blankenberg F.G., Sadeh M., Gilad R. Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia. Neurology 2006, 66:1253-1254.
30. Lau T.L., Ambroggio E.E., Tew D.J., Cappai R., Masters C.L., Fidelio G.D., Barnham K.J., Separovic F. Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J. Mol. Biol. 2006, 356:759-770.
31. Lee G., Pollard H.B., Arispe N. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 2002, 23:1249-1263.
32. Mason R.P., Shoemaker W.J., Shajenko L., Chambers T.E., Herbette L.G. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 1992, 13:413-419.
33. Masters C.L., Multhaup G., Simms G., Pottgiesser J., Martins R.N., Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985, 4:2757-2763.
34. Mukhopadhyay S., Cho W. Interactions of annexin V with phospholipid monolayers. Biochim. Biophys. Acta 1996, 1279:58-62.
35. Muller W.E., Kirsch C., Eckert G.P. Membrane-disordering effects of beta-amyloid peptides. Biochem. Soc. Trans. 2001, 29:617-623.
36. Nitsch R., Frotscher M. Reduction of posttraumatic transneuronal "early gene" activation and dendritic atrophy by the N-methyl-d-aspartate receptor antagonist MK-801. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:5197-5200.
37. Pomorski T., Holthuis J.C.M., Herrmann A., van Meer G. Tracking down lipid flippases and their biological functions. J. Cell. Sci. 2004, 117:805-813.
38. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
39. Simakova O., Arispe N.J. The cell-selective neurotoxicity of the Alzheimer's Aβ peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Abeta toxicity. J. Neurosci. 2007, 27:13719-13729.
40. Smith D.P., Ciccotosto G.D., Tew D.J., Fodero-Tavoletti M.T., Johanssen T., Masters C.L., Barnham K.J., Cappai R. Concentration dependent Cu(2+) induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry 2007, 46:2881-2891.
41. Smith D.P., Smith D.G., Curtain C.C., Boas J.F., Pilbrow J.R., Ciccotosto G.D., Lau T.L., Tew D.J., Perez K., Wade J.D., Bush A.I., Drew S.C., Separovic F., Masters C.L., Cappai R., Barnham K.J. Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J. Biol. Chem. 2006, 281:15145-15154.
42. Streltsov V.A., Titmuss S.J., Epa V.C., Barnham K.J., Masters C.L., Varghese J.N. The structure of the amyloid {beta}-peptide high affinity copper II binding site in Alzheimer's disease. Biophys. J. 2008, 95:3447-3456.
43. Syme C.D., Nadal R.C., Rigby S.E., Viles J.H. Copper binding to the amyloid-beta (Aβ) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Aβ-(1-28): insights from a range of complementary spectroscopic techniques. J. Biol. Chem. 2004, 279:18169-18177.
44. Tew D.J., Bottomley S.P., Smith D.P., Ciccotosto G.D., Babon J., Hinds M.G., Masters C.L., Cappai R., Barnham K.J. Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys. J. 2008, 94:2752-2766.
45. Tickler A.K., Smith D.G., Ciccotosto G.D., Tew D.J., Curtain C.C., Carrington D., Masters C.L., Bush A.I., Cherny R.A., Cappai R., Wade J.D., Barnham K.J. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J. Biol. Chem. 2005, 280:13355-13363.
46. Verdier Y., Penke B. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr. Protein Peptide Sci. 2004, 5:19-31.
47. Verdier Y., Zarandi M., Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Peptide Sci. 2004, 10:229-248.
48. Wang S.S., Rymer D.L., Good T.A. Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides. J. Biol. Chem. 2001, 276:42027-42034.
49. White A.R., Guirguis R., Brazier M.W., Jobling M.F., Hill A.F., Beyreuther K., Barrow C.J., Masters C.L., Collins S.J., Cappai R. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons. Neurobiol. Dis. 2001, 8:299-316.
50. Wiesehan K., Buder K., Linke R.P., Patt S., Stoldt M., Unger E., Schmitt B., Bucci E., Willbold D. Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide Aβ1-42 by mirror image phage display. Chembiochem. 2003, 4:748-753.
51. Yaar M., Zhai S., Fine R.E., Eisenhauer P.B., Arble B.L., Stewart K.B., Gilchrest B.A. Amyloid β binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J. Biol. Chem. 2002, 277:7720-7725.
52. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.